ETXPF Financial Statements From 2010 to 2026
| ETXPFDelisted Stock | USD 0.13 0.00 0.00% |
Check E Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among E Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . ETXPF financial statements analysis is a perfect complement when working with E Therapeutics Valuation or Volatility modules.
ETXPF |
E therapeutics Plc Company Current Valuation Analysis
E Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current E Therapeutics Current Valuation | 125.36 M |
Most of E Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, E therapeutics Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, E therapeutics Plc has a Current Valuation of 125.36 M. This is 99.13% lower than that of the Healthcare sector and 97.3% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.25% higher than that of the company.
E therapeutics Plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining E Therapeutics's current stock value. Our valuation model uses many indicators to compare E Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across E Therapeutics competition to find correlations between indicators driving E Therapeutics's intrinsic value. More Info.E therapeutics Plc is one of the top stocks in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the E Therapeutics' earnings, one of the primary drivers of an investment's value.About E Therapeutics Financial Statements
E Therapeutics stakeholders use historical fundamental indicators, such as E Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although E Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in E Therapeutics' assets and liabilities are reflected in the revenues and expenses on E Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in E therapeutics Plc. Please read more on our technical analysis and fundamental analysis pages.
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. The company was incorporated in 2001 and is based in London, the United Kingdom. E-Therapeutics Plc operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs people.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in ETXPF Pink Sheet
If you are still planning to invest in E therapeutics Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the E Therapeutics' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |